世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Pompe Disease Therapeutics Market  Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy), By Route of Administration (Oral, Parenteral), By End User (Hospitals & Speciality Clinics, Other), By Region, & Competition,  2020-2030F

Pompe Disease Therapeutics Market Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy), By Route of Administration (Oral, Parenteral), By End User (Hospitals & Speciality Clinics, Other), By Region, & Competition, 2020-2030F


Global Pompe Disease Therapeutics Market was valued at USD 1.50 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Pomp... もっと見る

 

 

出版社 出版年月 電子版価格 納期 ページ数 言語
TechSci Research
テックサイリサーチ
2025年3月28日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
PDF:2営業日程度 180 英語

 

Summary

Global Pompe Disease Therapeutics Market was valued at USD 1.50 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Pompe Disease Therapeutics Market is a rapidly evolving segment within the rare disease and orphan drug industry, driven by scientific advancements and increasing investment in innovative therapies. Pompe disease, or glycogen storage disease type II, is a rare lysosomal disorder caused by the deficiency of acid alpha-glucosidase (GAA), leading to glycogen accumulation in muscle tissues. This results in progressive muscle weakness and severe respiratory complications, necessitating targeted therapeutic interventions.
The market is primarily shaped by enzyme replacement therapies (ERTs) such as Myozyme (alglucosidase alfa), Lumizyme, and the more recent Nexviazyme (avalglucosidase alfa), which offer improved glycogen clearance and clinical outcomes. Additionally, the approval of Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat) in 2023 has expanded treatment options for patients, particularly those with late-onset Pompe disease (LOPD) who exhibit suboptimal responses to conventional ERTs.
Despite these advancements, market penetration is constrained by high treatment costs and limited newborn screening programs, leading to delayed diagnoses and disease progression. However, gene therapy and next-generation therapeutics are emerging as potential breakthroughs, with ongoing clinical trials aiming to provide more durable and cost-effective treatment alternatives.
Key Market Drivers
Increased Disease Awareness and Diagnosis
Pompe disease, often considered a rare or orphan disease, historically suffered from a lack of recognition and understanding. Pompe disease is a complex, multisystem genetic disorder with a prevalence of approximately 1 in 40,000 individuals in the United States. Increasing awareness of this rare condition is crucial, as early diagnosis and timely intervention can significantly improve patient outcomes and quality of life. Efforts to enhance disease recognition are being driven by medical institutions, patient advocacy groups, and biotech companies focused on expanding access to diagnostics and treatment. Newborn screening programs, physician education initiatives, and targeted awareness campaigns are playing a pivotal role in identifying patients earlier and facilitating access to advanced therapies. Patients faced delayed or misdiagnoses, leading to prolonged suffering and a dearth of effective treatments. Advocacy groups dedicated to Pompe disease have played a pivotal role in driving disease awareness. These organizations tirelessly work to raise public awareness, educate healthcare professionals, and provide support to affected individuals and their families. By leveraging social media, organizing awareness campaigns, and collaborating with healthcare institutions, these groups have succeeded in putting Pompe disease on the radar. The evolution of diagnostic technologies is another catalyst for increased disease awareness. Cutting-edge tools such as genetic testing and biomarker identification have revolutionized the diagnostic process. Physicians can now identify Pompe disease more accurately and swiftly, enabling timely intervention and treatment initiation. This, in turn, has elevated the importance of early diagnosis in improving patient outcomes.
Key Market Challenges
Limited Disease Awareness and Late Diagnosis
One of the foremost challenges in the Pompe Disease Therapeutics Market is the limited awareness of the disease itself, leading to delayed or missed diagnoses. Pompe disease is considered a rare condition, making it less well-known among healthcare professionals and the general public. This lack of awareness often results in late-stage diagnoses, which can significantly impact treatment outcomes.
Pompe disease's rarity, with an estimated incidence of 1 in 40,000 to 1 in 300,000 births, contributes to its obscurity. As healthcare professionals encounter rare diseases less frequently, the likelihood of prompt recognition and diagnosis diminishes. Pompe disease presents with symptoms that can overlap with those of other more common conditions, such as muscle weakness and respiratory problems. This lack of distinctiveness can lead to misdiagnoses or a failure to consider Pompe disease as a potential cause.
Key Market Trends
Personalized Medicine and Precision Therapies
One of the most significant trends in the Pompe Disease Therapeutics Market is the shift towards personalized medicine and precision therapies. Traditional treatment approaches often took a one-size-fits-all approach, but advancements in genetics and diagnostics have paved the way for tailored treatments that address the specific genetic mutations of individual patients. Advances in genetic research have provided insights into the precise genetic mutations that cause Pompe disease. This knowledge allows for the development of therapies that target the specific genetic defects in individual patients, maximizing treatment efficacy. Pharmaceutical companies are investing in innovative approaches, such as gene therapy and RNA-based therapies, that can be customized to target specific genetic mutations. These therapies hold the potential to correct the underlying genetic causes of Pompe disease. Advanced diagnostic tools, including genetic testing and biomarker identification, enable healthcare providers to identify the specific genetic mutations in Pompe disease patients. This information guides treatment decisions, ensuring that therapies are tailored to each patient's unique genetic profile.
Key Market Players
• Genzyme Corp
• Amicus Therapeutics Inc
• Valerion Therapeutics LLC
• Audentes Therapeutics Inc
• Actus Therapeutics Inc
• BioMarin Pharmaceutical Inc
• EpiVax inc
• Oxyrane Co Ltd.
• Sangamo BioSciences Inc
• Avrobio Inc
• Spark Therapeutics Inc
Report Scope:
In this report, the Global Pompe Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Pompe Disease Therapeutics Market, By Treatment Type:
o Drugs
o Enzyme Replacement Therapy
o Physical Therapy
o Chaperone-Advanced Replacement Therapy
• Pompe Disease Therapeutics Market, By Route of Administration:
o Oral
o Parenteral
• Pompe Disease Therapeutics Market, By End User:
o Hospitals & Speciality Clinics
o Other
• Pompe Disease Therapeutics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pompe Disease Therapeutics Market.
Available Customizations:
Global Pompe Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).


ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Pompe Disease Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy)
5.2.2. By Route of Administration (Oral, Parenteral)
5.2.3. By End User (Hospitals & Speciality Clinics, Other)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Pompe Disease Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Route of Administration
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Pompe Disease Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By End User
6.3.2. Canada Pompe Disease Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By End User
6.3.3. Mexico Pompe Disease Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By End User
7. Europe Pompe Disease Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Route of Administration
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pompe Disease Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By End User
7.3.2. United Kingdom Pompe Disease Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By End User
7.3.3. Italy Pompe Disease Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By End User
7.3.4. France Pompe Disease Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By End User
7.3.5. Spain Pompe Disease Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By End User
8. Asia-Pacific Pompe Disease Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Route of Administration
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pompe Disease Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By End User
8.3.2. India Pompe Disease Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By End User
8.3.3. Japan Pompe Disease Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By End User
8.3.4. South Korea Pompe Disease Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By End User
8.3.5. Australia Pompe Disease Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By End User
9. South America Pompe Disease Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Route of Administration
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pompe Disease Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By End User
9.3.2. Argentina Pompe Disease Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By End User
9.3.3. Colombia Pompe Disease Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By End User
10. Middle East and Africa Pompe Disease Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Route of Administration
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pompe Disease Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Pompe Disease Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By End User
10.3.3. UAE Pompe Disease Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Pompe Disease Therapeutics Market: SWOT Analysis
14. Competitive Landscape
14.1. Genzyme Corp
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Amicus Therapeutics Inc
14.3. Valerion Therapeutics LLC
14.4. Audentes Therapeutics Inc
14.5. Actus Therapeutics Inc
14.6. BioMarin Pharmaceutical Inc
14.7. EpiVax inc
14.8. Oxyrane Co Ltd.
14.9. Sangamo BioSciences Inc
14.10.Avrobio Inc
14.11.Spark Therapeutics Inc.
15. Strategic Recommendations
16. About Us & Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

TechSci Research社のヘルスケア分野での最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/08 10:26

148.77 円

163.31 円

192.60 円

ページTOPに戻る